Changes in Beneficial Ownership · 4
YD Bio Limited
YDESNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-14
- Issuer
- YD Bio Ltd
- Issuer CIK
- 0002011674
- Trading symbol
- YDES
Reporting owner 1
- Name
- Shen Ethan PhD
- Reporting owner CIK
- 0002099921
- Relationship
- Director · Officer
- Officer title
- CEO
- Address
- C/O YD BIO LIMITED, 12F., NO. 3, XINGNAN ST., NANGANG DIST., TAIPEI, TAIWAN, F5, 115001
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 2026-09-14 | P · Form 4 | 12,700 | A | 3.85[F1] | 11,258,331 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Ordinary Shares | 43,120,858 | I | See Footnotes[F2] |
Table key
- I
- Indirect
Footnotes
- F1
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.↩ 1
- F2
- The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.↩ 1
Signature 1
- Signed
- /s/ Ethan Shen
- Date
- 2026-09-16
Company context
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation - based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.